Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
ConditionMucormycosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorM.D. Anderson Cancer Center
About this trial
To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection.
Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care.
Disqualifiers
None
Trial population
MD Anderson Cancer Center
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Mucormycosis
BehavioralTell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).
Treatment groups
300 Participants
are divided into 4 treatment groupsGroup A: Group M1 intervention
Group B: Group A1 intervention
Group C: Group B1 intervention
Group D: Group C1 intervention
Trial outcomes
Primary outcomes
1
Safety and Adverse Events (AEs)
Time frame
Through study completion; an average of 1 year.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov